In-licensing Drugs for Personalized Medicine: What You Know, When You Know It
Executive Summary
Perlegen says it didn't make sense to do a costly genetic analysis on Mitsubishi's netoglitazone prior to getting rights to the drug. The decision highlights a dilemma for personalized medicine companies pursuing in-licensing, especially those attempting to differentiate a drug from others in its class: How do you assess a drug's potential before you actually have a chance to work with it?
You may also be interested in...
The Double-edged Sword of Diabetes Drug Development
Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.